نتائج البحث - David S. Mendelson

تنقيح النتائج
  1. 1
    Tumor angiogenesis and novel antiangiogenic strategies

    Tumor angiogenesis and novel antiangiogenic strategies حسب Michael S. Gordon, David S. Mendelson, Gerry Kato

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Image Sharing: Evolving Solutions in the Age of Interoperability

    Image Sharing: Evolving Solutions in the Age of Interoperability حسب David S. Mendelson, Bradley J. Erickson, Garry Choy

    منشور في 2014
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Pulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998–2010

    Pulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998–2010 حسب Theodore K. Marras, David S. Mendelson, Alex Marchand‐Austin, Kevin May, Frances Jamieson

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Enzyme Augmentation in Moderate to Life-Threatening Gaucher Disease

    Enzyme Augmentation in Moderate to Life-Threatening Gaucher Disease حسب Shari Fallet, Marie Grace, Arlyn Sibille, David S. Mendelson, Robert S Shapiro, George Hermann, Gregory A. Grabowski

    منشور في 1992
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Regional grey matter shrinks in hypertensive individuals despite successful lowering of blood pressure

    Regional grey matter shrinks in hypertensive individuals despite successful lowering of blood pressure حسب J. Richard Jennings, David N. Mendelson, Matthew F. Muldoon, Christopher M. Ryan, Peter J. Gianaros, Naftali Raz, Howard Aizenstein

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma

    Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma حسب Laurence H. Baker, Eric K. Rowinsky, David S. Mendelson, Rod Humerickhouse, Raymond A. Knight, Jiang Qian, Robert Carr, Gary Gordon, George D. Demetri

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Case Report: Lung Disease in World Trade Center Responders Exposed to Dust and Smoke: Carbon Nanotubes Found in the Lungs of World Trade Center Patients and Dust Samples

    Case Report: Lung Disease in World Trade Center Responders Exposed to Dust and Smoke: Carbon Nanotubes Found in the Lungs of World Trade Center Patients and Dust Samples حسب Maoxin Wu, Ronald E. Gordon, Robin Herbert, María L. Padilla, Jacqueline Moline, David S. Mendelson, Virginia R. Litle, William D. Travis, Joan Gil

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma

    Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma حسب Jimmy J. Hwang, John Kuruvilla, David S. Mendelson, Michael J. Pishvaian, John F. Deeken, Lillian L. Siu, Mark S. Berger, Jean Viallet, John L. Marshall

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Adjuvant and Salvage Radiotherapy After Prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline Endorsement

    Adjuvant and Salvage Radiotherapy After Prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline Endorsement حسب Stephen J. Freedland, R. Bryan Rumble, Antonio Finelli, Ronald C. Chen, Susan F. Slovin, Mark N. Stein, David S. Mendelson, Colin Wackett, Howard M. Sandler

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    A Prospective, Cross-sectional Survey Study of the Natural History of Niemann-Pick Disease Type B

    A Prospective, Cross-sectional Survey Study of the Natural History of Niemann-Pick Disease Type B حسب Margaret M. McGovern, Melissa Wasserstein, Roberto Giugliani, Bruno Bembi, Marie T. Vanier, Eugen Mengel, Scott E. Brodie, David S. Mendelson, Gwen Skloot, Robert J. Desnick, Noriko Kuriyama, Gerald F. Cox

    منشور في 2008
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors

    Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors حسب William P. Tew, Michael S. Gordon, John R. Murren, Jakob Dupont, S. Pezzulli, Carol Aghajanian, Paul Sabbatini, David S. Mendelson, Lawrence Schwartz, Scott Gettinger, Amanda Psyrri, Jesse M. Cedarbaum, David R. Spriggs

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    A Roadmap for Foundational Research on Artificial Intelligence in Medical Imaging: From the 2018 NIH/RSNA/ACR/The Academy Workshop

    A Roadmap for Foundational Research on Artificial Intelligence in Medical Imaging: From the 2018 NIH/RSNA/ACR/The Academy Workshop حسب Curtis P. Langlotz, Bibb Allen, Bradley J. Erickson, Jayashree Kalpathy‐Cramer, Keith Bigelow, Tessa S. Cook, Adam E. Flanders, Matthew P. Lungren, David S. Mendelson, Jeffrey D. Rudie, Ge Wang, Krishna Kandarpa

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer

    Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer حسب David B. Agus, Michael S. Gordon, Charles Taylor, Ronald B. Natale, Beth Y. Karlan, David S. Mendelson, Michael F. Press, David E. Allison, Mark X. Sliwkowski, Gracie Lieberman, Stephen M. Kelsey, Gwen Fyfe

    منشور في 2005
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

    A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer حسب Lee S. Rosen, Herbert I. Hurwitz, Michael K. Wong, Jonathan W. Goldman, David S. Mendelson, William D. Figg, Shawn D. Spencer, Bonne J. Adams, Delia Alvarez, Ben K. Seon, Charles P. Theuer, Bryan R. Leigh, Michael S. Gordon

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer

    An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer حسب Michael S. Gordon, Francisco Robert, Daniela Matei, David S. Mendelson, Jonathan W. Goldman, E. Gabriela Chiorean, Robert Matthew Strother, Ben K. Seon, William D. Figg, Cody J. Peer, Delia Alvarez, Bonne J. Adams, Charles P. Theuer, Lee S. Rosen

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progression From Taxane-Based Therapy

    Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progress... حسب David B. Agus, Christopher J. Sweeney, Michael J. Morris, David S. Mendelson, Douglas G. McNeel, Frederick R. Ahmann, Jin Wang, Mika K. Derynck, Kimmie Ng, Benjamin Lyons, David E. Allison, Michael W. Kattan, Howard I. Scher

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

    Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advan... حسب Michael S. Gordon, Christopher J. Sweeney, David S. Mendelson, S. Gail Eckhardt, Abraham Anderson, Darrin M. Beaupre, Daniel Branstetter, Teresa L. Burgess, Angela Coxon, Hongjie Deng, Paula Kaplan‐Lefko, Ian M. Leitch, Kelly S. Oliner, Lucy Yan, Min Zhu, Lia Gore

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

    A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab حسب Nancy U. Lin, Eric P. Winer, Duncan Wheatley, Lisa A. Carey, Stephen Houston, David S. Mendelson, Pamela N. Münster, Laurie Frakes, Steve Kelly, Agustin A. García, Susan Cleator, Martina Uttenreuther‐Fischer, H. Jones, Sven Wind, Richard Vinisko, Tamas Hickish

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer

    Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer حسب Johanna C. Bendell, Michael S. Gordon, Herbert I. Hurwitz, Suzanne F. Jones, David S. Mendelson, Gerard C. Blobe, Neeraj Agarwal, Carolyn H. Condon, Dawn Wilson, Amelia E. Pearsall, Yijun Yang, Ty McClure, Kenneth M. Attie, Matthew L. Sherman, Sunil Sharma

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline

    Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline حسب D.A. Loblaw, Katherine S. Virgo, Robert K. Nam, Mark R. Somerfield, Edgar Ben‐Josef, David S. Mendelson, Richard Middleton, Stewart A. Sharp, Thomas J. Smith, James A. Talcott, Mary‐Ellen Taplin, Nicholas J. Vogelzang, James L. Wade, Charles L. Bennett, Howard I. Scher

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: